Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 2/20 | 0.50 |
| ▸ | UTS2R | Q9UKP6 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.47 |
| ▸ | SCN1A | P35498 | 1/20 | 0.46 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2389374 | 0.91 | UTS2R (0.53) | UTS2RACHESMN1; SMN2 | |
| SCHEMBL18561731 | 0.87 | CCR3 (0.49) | CCR3UTS2RMEN1KMT2AACHE | |
| SCHEMBL14147057 | 0.85 | GAA (0.58) | CCR3UTS2RMEN1KMT2APOLB | |
| SCHEMBL2388985 | 0.84 | MEN1 (0.52) | MEN1KMT2ADRD4POLBSMN1; SMN2 | |
| SCHEMBL2392556 | 0.84 | CYP2D6 (0.59) | CCR3UTS2RMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2387564 | 0.81 | ADRB2 (0.59) | MEN1KMT2ADRD4PRKAA2 | |
| SCHEMBL2389659 | 0.81 | SCN1A (0.56) | CCR3UTS2RMEN1KMT2ADRD4 | |
| SCHEMBL2388680 | 0.80 | DRD4 (0.69) | UTS2RMEN1KMT2AACHEDRD4 | |
| SCHEMBL2390955 | 0.80 | HRH1 (0.58) | CCR3UTS2RMEN1KMT2ADRD4 | |
| SCHEMBL17946117 | 0.79 | UTS2R (0.55) | CCR3UTS2RMEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2079694-B1 | N-SUBSTITUTED-HETEROCYCLOALKYLOXYBENZAMIDE COMPOUNDS AND METHODS OF USE | RIGEL PHARMACEUTICALS INC (US) | 2017-03-01 | — | — | EP | disclosed |
| EP-2079694-B1 | N-SUBSTITUTED-HETEROCYCLOALKYLOXYBENZAMIDE COMPOUNDS AND METHODS OF USE | RIGEL PHARMACEUTICALS INC (US) | 2017-03-01 | — | — | EP | disclosed |
| US-9511058-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9409884-B2 | 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9181220-B2 | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2015-11-10 | — | — | US | disclosed |
| US-20140378429-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using Them | RIGEL PHARMACEUTICALS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| US-20140323460-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | MIDCAP FINANCIAL TRUST | 2014-10-30 | — | — | US | disclosed |
| US-8796254-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2014-08-05 | — | — | US | disclosed |
| US-20140179738-A1 | N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2014-06-26 | — | — | US | disclosed |
| US-8697727-B2 | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2014-04-15 | — | — | US | disclosed |
| US-20110306767-A1 | N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| US-8012955-B2 | N-substituted-heterocycloalkyloxybenzamide compounds and methods of use | RIGEL PHARMACEUTICALS, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20090186894-A1 | N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use | RIGEL PHARMACEUTICALS, INC. (US) | 2009-07-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | CS, SHMT2, GOT2 | CCR3 3758/4885UTS2R 1156/4885MEN1 4748/4885 |
| US-20110306767-A1 | N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use | PRKAG2, PRKAB2, PRKAG1 | CCR3 3454/4885UTS2R 1914/4885MEN1 3006/4885 |
| US-20140323460-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | CS, SHMT2, GOT2 | CCR3 3758/4885UTS2R 1156/4885MEN1 4748/4885 |
| US-20140179738-A1 | N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use | PRKAG2, PRKAB2, PRKAG1 | CCR3 3454/4885UTS2R 1914/4885MEN1 3006/4885 |
| US-20090186894-A1 | N-Substituted-Heterocycloalkyloxybenzamide Compounds and Methods of Use | PRKAG2, PRKAB2, PRKAG1 | CCR3 3454/4885UTS2R 1914/4885MEN1 3006/4885 |
| US-20140378429-A1 | Carboxamide, Sulfonamide and Amine Compounds and Methods for Using Them | CPT2, SHMT2, CS | CCR3 3598/4885UTS2R 1064/4885MEN1 3859/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.